Health-Related Quality of Life in Patients With Schizophrenia During Treatment With Long-Acting, Injectable Risperidone

Nasrallah, Henry A.; Duchesne, I.; Mehnert, A.; Janagap, C.; Eerdekens, Mariëlle

doi:10.4088/jcp.v65n0412

Cited by 85 publications

(65 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LAI preparations offer important options for treatment of chronic diseases and are particularly important for enhancing adherence, which may in turn benefit treatment outcomes and quality of life (Bhanji et al, 2004;Love, 2002;Marinis et al, 2007;Nasrallah et al, 2004). Adherence to treatment is probably a major reason for the lower risk for relapse with LAI formulations vs oral antipsychotic therapy.…”

Section: Discussionmentioning

confidence: 99%

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Nasrallah

Gopal

Gassmann-Mayer

et al. 2010

Neuropsychopharmacol

Self Cite

137

View full text Add to dashboard Cite

Paliperidone palmitate is a long-acting injectable antipsychotic agent. This 13-week, multicenter, randomized (1 : 1 : 1 : 1), double-blind, parallel-group study evaluated the efficacy, safety, and tolerability of fixed 25, 50, and 100 milligram equivalent (mg equiv.) doses of paliperidone palmitate vs placebo administered as gluteal injections on days 1 and 8, then every 4 weeks (days 36 and 64) in 518 adult patients with schizophrenia. The intent-to-treat analysis set (N ¼ 514) was 67% men and 67% White, with a mean age of 41 years. All paliperidone palmitate dose groups showed significant improvement vs placebo in the Positive and Negative Syndrome Scale (PANSS) total score (primary efficacy measure; 25 and 50 mg equiv., p ¼ 0.02; 100 mg equiv., po0.001), as well as Clinical Global Impression Severity scores (pp0.006) and PANSS negative and positive symptom Marder factor scores (pp0.04). The Personal and Social Performance scale showed no significant difference between treatment groups. The overall incidence of treatment-emergent adverse events was similar between groups. Parkinsonism, the most frequently reported extrapyramidal symptom, was reported at similar rates for placebo (5%) and paliperidone palmitate (5-6% across doses). The mean body mass index and mean weight showed relatively small dose-related increases during paliperidone palmitate treatment. Investigator-evaluated injection-site pain, swelling, redness, and induration were similar across treatment groups; scores for patient-evaluated injection-site pain (visual analog scale) were similar across groups and diminished with time. All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated, both locally and systemically. Paliperidone palmitate offers the potential to improve outcomes in adults with symptomatic schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

Nasrallah

Gopal

Gassmann-Mayer

et al. 2010

Neuropsychopharmacol

Self Cite

137

View full text Add to dashboard Cite

show abstract

“…66,67,[69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85]88,[92][93][94][95] Although there appears to be strong evidence that the SF-36 is able to distinguish between general population norms and scores of people with schizophrenia (known-group validity), the evidence for convergent validity and responsiveness is less certain ( Table 4). Similar findings exist for the EQ-5D, with mixed evidence for the properties of convergent validity and responsiveness.…”

Section: Schizophreniamentioning

confidence: 99%

“…Participants included males and females with a mean age of participants with a schizophrenia spectrum disorder, reported in 21 of the 33 studies, ranging between 20.3 and 57.9 years. 48,68,[70][71][72][73][75][76][77][78][79][80]82,84,86,[88][89][90][91]94,95 All studies obtained HRQoL information from patients; seven of these studies compared patient HRQoL values with published general population 'normative' values, [70][71][72][73][74][75][76] three compared HRQoL values with normal comparison participants that were recruited to the study [77][78][79] and two used 'norms' from healthy participants who had taken part in large surveys.…”

Section: Schizophreniamentioning

confidence: 99%

A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures

Brazier

Connell

Papaioannou

et al. 2014

Health Technology Assessment

211

187

View full text Add to dashboard Cite

This report should be referenced as follows:Brazier J, Connell J, Papaioannou D, Mukuria C, Mulhern B, Peasgood T, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess 2014;18(34). This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment is indexed and abstracted inEditorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme or, commissioned/managed through the Methodology research programme (MRP), and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions. To strengthen the evidence base for health research, the MRP oversees and implements the evolving strategy for high quality methodological research. In addition to the MRC and NIHR funding partners, the MRP takes into account the needs of other stakeholders including the devolved administrations, industry R&D, and regulatory/advisory agencies and other public bodies. The MRP funds investigator-led and needsled research proposals from across the UK. In addition to the standard MRC and RCUK terms and conditions, projects commissioned/managed by the MRP are expected to provide a detailed report on the research findings and may publish the findings in the HTA journal, if supported by NIHR funds.The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy o...

show abstract

“…Numerous studies have been conducted with narrower approaches, focusing on the concept of health related quality of life (HRQoL) (12)(13) , using tools like the Drug Attitude Inventory (14) , the Global Assessment of Relational Functioning Scale (15) , the SF-36 Health Questionnaire (16) , the Lancashire Quality of Life Profile (17) and also large instruments created ad hoc (18) . Most of these studies present a practical and common problem, which is the difficulty to translate the evaluations into plans of care, and to obtain results of quality of life, from the identification of the support needs of a person, i.e.…”

Section: Introductionmentioning

confidence: 99%

Applicability of the Spanish Version of the Supports Intensity Scale (SIS), in the Mexican Population with Severe Mental Illness

Ortiz

Río

Rodríguez

et al. 2010

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

This study presents the results obtained from the evaluation, by specialist judges, of the Supports Intensity Scale (SIS), Spanish version, to determine its suitability for the Mexican population with severe mental illness (SMI). The instrument, originally designed for people with intellectual disabilities, is consistent with the multidimensional concept of quality of life and the social model of disability. The semantic equivalence of the items adjusted by specialist judges, the reliability of the subscales, using Cronbach's alpha, and the concurrent validity between the SIS and the Global Functioning Assessment (GAF) were analyzed. The mean similarity to the original was 9.91 from a total of 10 (sd=0.14). The reliability coefficients were above 0.95 and the correlations between the SIS and the GAF were medium to high and significant. In conclusion, in the Mexican context, the SIS scale can be used to understand the needs and expectations of people with mental illness.

show abstract

Health-Related Quality of Life in Patients With Schizophrenia During Treatment With Long-Acting, Injectable Risperidone

Cited by 85 publications

References 0 publications

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures

Applicability of the Spanish Version of the Supports Intensity Scale (SIS), in the Mexican Population with Severe Mental Illness

Contact Info

Product

Resources

About